(Total Views: 388)
Posted On: 02/14/2018 8:29:34 AM
Post# of 30066
.jpg)
The Renishaw device appears to work:
https://www.arvopaperi.fi/kaikki_uutiset/hera...sa-6701659
google translation:
The first clinical trial of Herantis Pharma's CDNF has progressed to the first independent safety assessment committee's expert committee. This product is intended for the treatment of Parkinson's.
The Committee recommends continuing the study as planned. Thus, two new research centers, Helsinki and Skåne University hospitals, will begin recruiting patients alongside the Karolinska University Hospital in Stockholm.
"CDNF dosing for clinical trials for the first time in the world is a major milestone for our company," says Sigrid Booms, Head of Clinical Development at Herantis.
The company's goal is to recruit all patients by the end of the year.
A randomized, placebo-controlled clinical study of CDNF research is recruited for 18 patients. These patients are also offered the opportunity to participate in a further study, where everyone gets CDNF treatment. Further research requires separate authority approval.
https://www.arvopaperi.fi/kaikki_uutiset/hera...sa-6701659
google translation:
The first clinical trial of Herantis Pharma's CDNF has progressed to the first independent safety assessment committee's expert committee. This product is intended for the treatment of Parkinson's.
The Committee recommends continuing the study as planned. Thus, two new research centers, Helsinki and Skåne University hospitals, will begin recruiting patients alongside the Karolinska University Hospital in Stockholm.
"CDNF dosing for clinical trials for the first time in the world is a major milestone for our company," says Sigrid Booms, Head of Clinical Development at Herantis.
The company's goal is to recruit all patients by the end of the year.
A randomized, placebo-controlled clinical study of CDNF research is recruited for 18 patients. These patients are also offered the opportunity to participate in a further study, where everyone gets CDNF treatment. Further research requires separate authority approval.
(4)
(0)
